keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/28814462/-18-f-av-1451-binds-to-motor-related-subcortical-gray-and-white-matter-in-corticobasal-syndrome
#1
Hanna Cho, Min Seok Baek, Jae Yong Choi, Seung Ha Lee, Joong Seok Kim, Young Hoon Ryu, Myung Sik Lee, Chul Hyoung Lyoo
OBJECTIVE: To investigate tau distribution in patients with corticobasal syndrome (CBS) using (18)F-AV-1451 PET. METHODS: Six consecutively recruited patients with CBS and 20 age-matched healthy controls underwent 2 PET scans with (18)F-AV-1451 (for tau) and (18)F-florbetaben (for β-amyloid). We compared standardized uptake value ratio maps of the (18)F-AV-1451 PET images between the patients with CBS and controls. RESULTS: Compared to controls, patients with CBS exhibited asymmetrically increased (18)F-AV-1451 binding in the putamen, globus pallidus, and thalamus contralateral to the clinically more affected side and in the ipsilateral globus pallidus and dentate nucleus...
August 16, 2017: Neurology
https://www.readbyqxmd.com/read/28808912/molecular-imaging-and-updated-diagnostic-criteria-in-lewy-body-dementias
#2
REVIEW
Nicolaas I Bohnen, Martijn L T M Müller, Kirk A Frey
PURPOSE OF REVIEW: The aims of the study were to review recent advances in molecular imaging in the Lewy body dementias (LBD) and determine if these may support the clinical but contested temporal profile distinction between Parkinson disease (PD) with dementia (PDD) versus dementia with Lewy bodies (DLB). RECENT FINDINGS: There do not appear to be major regional cerebral metabolic or neurotransmitter distinctions between PDD and DLB. However, recent studies highlight the relative discriminating roles of Alzheimer proteinopathies...
August 14, 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28803444/atypical-parkinsonian-syndromes-a-general-neurologist-s-perspective
#3
REVIEW
Angela B Deutschländer, Owen A Ross, Dennis W Dickson, Zbigniew K Wszolek
The differential diagnosis of atypical parkinsonian syndromes is challenging. These severe and often rapidly progressive neurodegenerative disorders are clinically heterogeneous and show significant phenotypic overlap. Here we review clinical, imaging, neuropathologic and genetic features of multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal lobar degeneration (FTLD). The terms CBD and FTLD refer to pathologically confirmed cases of corticobasal syndrome (CBS) and frontotemporal dementia (FTD)...
August 12, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28800330/pet-tau-and-amyloid-%C3%AE-burden-in-mild-alzheimer-s-disease-divergent-relationship-with-age-cognition-and-cerebrospinal-fluid-biomarkers
#4
Ivan Koychev, Roger N Gunn, Azadeh Firouzian, Jennifer Lawson, Giovanna Zamboni, Basil Ridha, Barbara J Sahakian, James B Rowe, Alan Thomas, Lynn Rochester, Dominic Ffytche, Robert Howard, Henrik Zetterberg, Clare MacKay, Simon Lovestone
BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline...
August 8, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28790016/tau-imaging-in-neurodegeneration
#5
REVIEW
Gérard N Bischof, Heike Endepols, Thilo van Eimeren, Alexander Drzezga
Pathological cerebral aggregations of proteins are suggested to play a crucial role in the development of neurodegenerative disorders. For example, aggregation of the protein ß-amyloid in form of extracellular amyloid-plaques as well as intraneuronal depositions of the protein tau in form of neurofibrillary tangles represent hallmarks of Alzheimer's disease (AD). Recently, novel tracers for in vivo molecular imaging of tau-aggregates in the brain have been introduced, complementing existing tracers for imaging amyloid-plaques...
August 5, 2017: Methods: a Companion to Methods in Enzymology
https://www.readbyqxmd.com/read/28758146/effects-of-traumatic-brain-injury-and-posttraumatic-stress-disorder-on-development-of-alzheimer-s-disease-in-vietnam-veterans-using-the-alzheimer-s-disease-neuroimaging-initiative-preliminary-report
#6
Michael W Weiner, Danielle Harvey, Jacqueline Hayes, Susan M Landau, Paul S Aisen, Ronald C Petersen, Duygu Tosun, Dallas P Veitch, Clifford R Jack, Charles Decarli, Andrew J Saykin, Jordan Grafman, Thomas C Neylanthe
INTRODUCTION: Traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD) have previously been reported to be associated with increased risk of Alzheimer's disease (AD). We are using biomarkers to study Vietnam Veterans with/without mild cognitive impairment with a history of at least one TBI and/or ongoing PTSD to determine whether these contribute to the development of AD. METHODS: Potential subjects identified by Veterans Administration records underwent an initial telephone screen...
June 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/28756238/av-1451-pet-imaging-of-tau-pathology-in-preclinical-alzheimer-disease-defining-a-summary-measure
#7
Shruti Mishra, Brian A Gordon, Yi Su, Jon Christensen, Karl Friedrichsen, Kelley Jackson, Russ Hornbeck, David A Balota, Nigel J Cairns, John C Morris, Beau M Ances, Tammie L S Benzinger
Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are most important in detecting elevated tau pathology in preclinical AD. Here, we utilized an unsupervised learning, data-driven approach to identify brain regions whose tau PET is most informative in discriminating low and high levels of [18F]-AV-1451 binding. 84 cognitively normal participants who had undergone AV-1451 PET imaging were used in a sparse k-means clustering with resampling analysis to identify the regions most informative in dividing a cognitively normal population into high tau and low tau groups...
July 26, 2017: NeuroImage
https://www.readbyqxmd.com/read/28750496/tau-imaging-with-pet-an-overview-of-challenges-current-progress-and-future-applications
#8
Joanne S Robertson, Christopher C Rowe, Victor L Villemagne
Folded and misfolded tau is common to many neurodegenerative conditions, collectively termed 'tauopathies'. In recent years, many efforts have contributed toward development of tau imaging agents to allow measurement of tau deposits in vivo using Positron Emission Tomography (PET). The particularities of tau present some unique challenges for the development of tau imaging tracers. Most notably, these pertain to the predominantly intracellular nature of tau aggregations, the existence of six isoforms, multiple post-translational modification, and that tau is usually surrounded by larger concentrations of A plaques...
July 27, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28747523/-18-f-flortaucipir-pet-mri-correlations-in-non-amnestic-and-amnestic-variants-of-alzheimer-disease
#9
Ilya M Nasrallah, Yin Jie Chen, Meng-Kang Hsieh, Jeffrey S Philips, Kylie Ternes, Grace Stockbower, Yvette Sheline, Corey T McMillan, Murray Grossman, David A Wolk
Non-amnestic Alzheimer disease (AD) variants, including posterior cortical atrophy (PCA) and logopenic variant of primary progressive aphasia (lvPPA), differ in distributions of tau aggregates and neurodegeneration compared to amnestic AD. We evaluated whether (18)F-flortaucipir (also called (18)F-AV-1451) Positron Emission Tomography (PET), targeting tau aggregates, detects these differences and compared this to magnetic resonance imaging (MRI) measures of gray matter (GM) atrophy. Methods: 5 PCA, 4 lvPPA, 6 age-matched AD, and 6 control subjects underwent (18)F-flortaucipir PET and MRI...
July 26, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28743782/-18-f-av-1451-and-csf-t-tau-and-p-tau-as-biomarkers-in-alzheimer-s-disease
#10
Niklas Mattsson, Michael Schöll, Olof Strandberg, Ruben Smith, Sebastian Palmqvist, Philip S Insel, Douglas Hägerström, Tomas Ohlsson, Henrik Zetterberg, Jonas Jögi, Kaj Blennow, Oskar Hansson
To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand (18)F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of (18)F-AV-1451, and mainly in demented AD patients. (18)F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment...
July 25, 2017: EMBO Molecular Medicine
https://www.readbyqxmd.com/read/28740088/functional-correlates-of-tsh-ft3-and-ft4-in-alzheimer-disease-a-f-18-fdg-pet-ct-study
#11
Agostino Chiaravalloti, Francesco Ursini, Alessandro Fiorentini, Gaetano Barbagallo, Alessandro Martorana, Giacomo Koch, Mario Tavolozza, Orazio Schillaci
The present study was aimed to investigate the relationships between thyroid stimulating hormone (TSH), freeT3 (fT3) and freeT4 (fT4) and brain glucose consumption as detectable by means of 2-deoxy-2-(F-18) fluoro-D-glucose (F-18 FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in a selected population with Alzheimer disease (AD). We evaluated 87 subjects (37 males and 50 females, mean age 70 (±6) years old) with AD. All of them were subjected to TSH, fT3 and fT4 assay and to cerebrospinal fluid amyloid (Aβ1-42) and tau [phosphorylated-tau (p-tau) and total-tau (t-tau)] assay prior PET/CT examination...
July 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28733960/a-review-of-fluid-biomarkers-for-alzheimer-s-disease-moving-from-csf-to-blood
#12
REVIEW
Kaj Blennow
A set of core cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) includes total tau (T-tau), phosphorylated tau (P-tau) and β-amyloid 42 (Aβ42). These biomarkers reflect some of the key aspects of AD pathophysiology, including neuronal degeneration, tau phosphorylation with tangle formation, and Aβ aggregation with deposition of the peptide into plaques. The core AD CSF biomarkers have been validated clinically in numerous studies, and found to have a very high diagnostic performance to identify AD, both in the dementia and in the mild cognitive impairment stages of the disease...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28733959/increasing-precision-of-clinical-diagnosis-of-alzheimer-s-disease-using-a-combined-algorithm-incorporating-clinical-and-novel-biomarker-data
#13
REVIEW
Marwan N Sabbagh, Lih-Fen Lue, Daniel Fayard, Jiong Shi
Establishing the in vivo diagnosis of Alzheimer's disease (AD) or other dementias relies on clinical criteria; however, the accuracy of these criteria can be limited. The diagnostic accuracy is 77% for a clinical diagnosis of AD, even among experts. We performed a review through PubMed of articles related to specific diagnostic modalities, including APOE genotyping, cerebrospinal fluid (CSF) testing, fludeoxyglucose F 18 positron emission tomography (PET), amyloid PET, tau PET, computed tomography (CT), single-photon emission CT, magnetic resonance imaging (MRI), and B12 and thyroid-stimulating hormone screening, to determine the specificity and sensitivity of each test used in the clinical diagnosis of AD...
July 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28697559/depressive-symptoms-and-tau-accumulation-in-the-inferior-temporal-lobe-and-entorhinal-cortex-in-cognitively-normal-older-adults-a-pilot-study
#14
Jennifer R Gatchel, Nancy J Donovan, Joseph J Locascio, Aaron P Schultz, J Alex Becker, Jasmeer Chhatwal, Kathryn V Papp, Rebecca E Amariglio, Dorene M Rentz, Deborah Blacker, Reisa A Sperling, Keith A Johnson, Gad A Marshall
BACKGROUND: Depressive symptoms are common in older adults and associated with increased morbidity and cognitive decline. These symptoms occur during preclinical and prodromal stages of Alzheimer's disease (AD), but their relationship to tau, one of the main AD proteinopathies, is poorly understood. OBJECTIVE: The objective of this study was to investigate the cross-sectional association between depressive symptoms and cerebral tau [18F T807 (also known as 18F-AV-1451) tau positron emission tomography (PET) imaging] in cognitively normal (CN) older adults...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28690634/preventive-effect-of-rifampicin-on-alzheimer-disease-needs-at-least-450-mg-daily-for-1-year-an-fdg-pet-follow-up-study
#15
Tomomichi Iizuka, Kozo Morimoto, Yuka Sasaki, Masashi Kameyama, Atsuyuki Kurashima, Kazumasa Hayasaka, Hideo Ogata, Hajime Goto
BACKGROUND: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed (18)F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. METHODS: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled...
May 2017: Dementia and Geriatric Cognitive Disorders Extra
https://www.readbyqxmd.com/read/28689050/self-reported-traumatic-brain-injury-and-in-vivo-measure-of-ad-vulnerable-cortical-thickness-and-ad-related-biomarkers-in-the-adni-cohort
#16
Ming-Liang Wang, Xiao-Er Wei, Meng-Meng Yu, Peng-Yang Li, Wen-Bin Li
In this study, we aimed to investigate whether self-reported mild traumatic brain injury (mTBI) was associated with decreased AD-vulnerable cortical thickness, and to assess the relationship between AD-vulnerable cortical thickness and AD-related biomarker in the Alzheimer's Disease Neuroimaging Initiative subjects. We identified 45 self-reported mTBI subjects, who had structural MRI, 18F-AV45 PET, and cerebrospinal fluid (CSF) data. Of them, eight subjects were normal; ten were preclinical AD; seventeen were MCI due to AD; ten were AD...
August 10, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28654263/identification-of-three-novel-radiotracers-for-imaging-aggregated-tau-in-alzheimer-s-disease-with-positron-emission-tomography
#17
Luca C Gobbi, Henner Knust, Matthias Körner, Michael Honer, Christian Czech, Sara Belli, Dieter Muri, Martin R Edelmann, Thomas Hartung, Isabella Erbsmehl, Sandra Grall-Ulsemer, Andreas Koblet, Marianne Rueher, Sandra Steiner, Hayden T Ravert, William B Mathews, Daniel P Holt, Hiroto Kuwabara, Heather Valentine, Robert F Dannals, Dean F Wong, Edilio Borroni
Aggregates of tau and beta amyloid (Aβ) plaques constitute the histopathological hallmarks of Alzheimer's disease and are prominent targets for novel therapeutics as well as for biomarkers for diagnostic in vivo imaging. In recent years much attention has been devoted to the discovery and development of new PET tracers to image tau aggregates in the living human brain. Access to a selective PET tracer to image and quantify tau aggregates represents a unique tool to support the development of any novel therapeutic agent targeting pathological forms of tau...
July 12, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28652213/the-efficacy-of-18-f-fdg-pet-ct-and-67-ga-spect-ct-in-diagnosing-fever-of-unknown-origin
#18
Bor-Tau Hung, Pei-Wen Wang, Yu-Jih Su, Wen-Chi Huang, Yen-Hsiang Chang, Shu-Hua Huang, Chiung-Chih Chang
OBJECTIVE: Fever of unknown origin (FUO) is a diagnostic challenge. This study aimed to assess the efficacy of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) and gallium-67 single-photon emission computed tomography/computed tomography ((67)Ga SPECT/CT) in diagnosing FUO. METHODS: A total of 68 patients with FUO underwent (18)F-FDG PET/CT and (67)Ga SPECT/CT from January 2013 through May 2016. Images were read independently...
June 23, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28645685/concordance-between-brain-18-f-fdg-pet-and-cerebrospinal-fluid-biomarkers-in-diagnosing-alzheimer-s-disease
#19
S Rubí, A Noguera, S Tarongí, M Oporto, A García, H Vico, A Espino, M J Picado, A Mas, C Peña, G Amer
OBJECTIVES: Cortical posterior hypometabolism on PET imaging with (18)F-FDG (FDG-PET), and altered levels of Aß1-42 peptide, total Tau (tTau) and phosphorylated Tau (pTau) proteins in cerebrospinal fluid (CSF) are established diagnostic biomarkers in Alzheimer's disease (AD). An evaluation has been made of the concordance and relationship between the results of FDG-PET and CSF biomarkers in symptomatic patients with suspected AD. MATERIAL AND METHODS: A retrospective review was carried out on 120 patients with cognitive impairment referred to our Cognitive Neurology Unit, and who were evaluated by brain FDG-PET and a lumbar puncture for CSF biomarkers...
June 20, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28640595/detection-and-characterization-of-small-molecule-interactions-with-fibrillar-protein-aggregates-using-microscale-thermophoresis
#20
Emily Fisher, Yanyan Zhao, Robert Richardson, Malgorzata Janik, Alexander K Buell, Franklin I Aigbirhio, Gergely Tóth
Neurodegenerative diseases such as Parkinson's and Alzheimer's disease share the pathological hallmark of fibrillar protein aggregates. The specific detection of these protein aggregates by positron emission tomography (PET) in the patient brain can yield valuable information for diagnosis and disease progression. However, the identification of novel small compounds that bind fibrillar protein aggregates has been a challenge. In this study, microscale thermophoresis (MST) was applied to assess the binding affinity of known small molecule ligands of α-synuclein fibrils, which were also tested in parallel in a thioflavin T fluorescence competition assay for further validation...
July 6, 2017: ACS Chemical Neuroscience
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"